November 11, 2021
Japan’s all-important reimbursement policy panel on November 10 approved the results of cost-effectiveness assessments (CEAs) for MSD’s antifungal agent Noxafil (posaconazole), putting it in line for a downward price adjustment. Under the CEA scheme, which was introduced for post-launch price...read more